Abstract-Few data are available on the predictors of decline in antihypertensive medication adherence and the association of decline in adherence with subsequent blood pressure (BP) control. A lthough there has been progress in the prevention, detection, awareness, and treatment of hypertension, it persists as a major public health challenge affecting Ϸ65 million people in the United States and Ͼ1 billion people worldwide. 1-3 Effective medical therapies exist; yet, only 69% of US adults treated for hypertension have controlled blood pressure (BP). 2 Low adherence to prescribed medications has been implicated as one of the major contributors to uncontrolled BP. 4 -6 Hypertension requires continuous adherence (ie, persistence) to pharmacological treatment over time to achieve and maintain BP control and reduce the risk for cardiovascular disease and related deaths. [7] [8] [9] In a Canadian cohort, persistence with antihypertensive medications, assessed using prescription data for patients with established hypertension, was only 82% at 4.5 years 10 ; BP data and risk factors for nonpersistence beyond age and sex were not reported. A decline in antihypertensive medication adherence over time could negatively impact hypertension control; thus, data on the association among decline in adherence, BP control, and potential risk factors are needed.
A lthough there has been progress in the prevention, detection, awareness, and treatment of hypertension, it persists as a major public health challenge affecting Ϸ65 million people in the United States and Ͼ1 billion people worldwide. [1] [2] [3] Effective medical therapies exist; yet, only 69% of US adults treated for hypertension have controlled blood pressure (BP). 2 Low adherence to prescribed medications has been implicated as one of the major contributors to uncontrolled BP. 4 -6 Hypertension requires continuous adherence (ie, persistence) to pharmacological treatment over time to achieve and maintain BP control and reduce the risk for cardiovascular disease and related deaths. [7] [8] [9] In a Canadian cohort, persistence with antihypertensive medications, assessed using prescription data for patients with established hypertension, was only 82% at 4.5 years 10 ; BP data and risk factors for nonpersistence beyond age and sex were not reported. A decline in antihypertensive medication adherence over time could negatively impact hypertension control; thus, data on the association among decline in adherence, BP control, and potential risk factors are needed.
A conceptual model outlining risk factors associated with poor adherence and uncontrolled hypertension has been described previously. 11 A decline in adherence reflects a change in behavior over time, and risk factors predicting decline may differ from those that are associated with poor adherence at one point in time. However, few data are available regarding the decline in adherence over time and its associated risk factors.
We assessed the rate of decline in self-reported antihypertensive medication adherence over 2 years of follow-up and its association with BP control and risk factors in older adults with established hypertension. We hypothesized that a decline in self-reported antihypertensive medication adherence would be associated with worsening of BP and sought to identify factors associated with a decline in adherence. To address these hypotheses, we analyzed data from communitydwelling participants Ն65 years of age enrolled in the Cohort Study of Medication Adherence Among Older Adults (CoSMO). 6 
Methods

Study Population and Time Line
The CoSMO study design, recruitment flow chart, response rates, and baseline characteristics of participants have been described previously. 6 In brief, adults Ն65 years of age under treatment for essential hypertension were randomly selected from the roster of a large managed care organization in southeastern Louisiana. Between August 2006 and September 2007, 2194 individuals were recruited and completed a baseline survey. Participants were resurveyed 1 and 2 years later. The recapture rate was 93.6% for the follow-up surveys.
The present analysis includes data from the baseline and 2 follow-up surveys and was limited to 1965 participants who completed the baseline and first follow-up survey. There were 1756 CoSMO participants who did not experience a decline in medication adherence by the first follow-up and were considered at risk for the second time period. There were no differences by age, sex, race, marital status, education, comorbidity, or hypertension duration between CoSMO participants excluded from the analyses (primarily for nonresponse to the first follow-up survey) and participants included in this analysis (PϾ0.10 for all of the comparisons). All of the participants provided verbal informed consent, 6, 12 and CoSMO was approved by the Ochsner Clinic Foundation Institutional Review Board and the privacy board of the managed care organization.
Study Measures
Based on a conceptual model, 11 items (eg, sociodemographic, psychosocial, treatment, clinical, healthcare system, and unconventional therapies) were included in the baseline and the follow-up surveys, which were administered by telephone using trained interviewers and lasted 30 to 45 minutes. In addition, information regarding comorbid conditions and pharmacy fills (include drug name, date filled, drug class, and drug tier) for antihypertensive medications was obtained from the administrative databases of the managed care organization.
Sociodemographic, Clinical, and Treatment Factors
Age, sex, race, marital status, education, height and weight (for calculation of body mass index), and duration of hypertension were obtained through self-report. Hypertension knowledge was assessed using a validated tool; participants with scores in the lowest tertile were defined as having low knowledge. 13, 14 Comorbid conditions were identified; the Charlson comorbidity index score was calculated and dichotomized as Ͻ2 versus Ն2. 15 The number and classes of antihypertensive medications filled in the year before the baseline survey were categorized as Ͻ3 versus Ն3. Each component of combination medications was classified in its respective class. The use of antihypertensive medication was defined as having Ն90 days of medication within the medication class in the previous year.
Healthcare System Variables
Participants "not satisfied" with health care were defined as having a poor or fair satisfaction score using 3 scales of the Group Health Association of America Consumer Satisfaction Survey. 16 Participants were asked whether they had reduced antihypertensive medication because of the cost. Number of visits to a primary healthcare provider in the year before each survey was captured by self-report and dichotomized as Ͻ6 versus Ն6. As a surrogate for medication costs, fill of an antihypertensive medication in drug tier 3 (reflecting higher medication costs) versus fills in drug tier 1 or 2 (reflecting lower medication costs) only was captured in the pharmacy database.
Psychosocial/Behavioral Variables
Cigarette smoking 17 and alcohol use were assessed via self-report. Reduced sexual functioning was defined as values below the median for the sample on the Massachusetts General Hospital Sexual Functioning Questionnaire. 18 The presence of depressive symptoms was defined as a score of Ն16 using the Center for Epidemiological Studies Depression Scale. 19 Low social support was defined as scores in the lowest tertile using the RAND Medical Outcomes Study Social Support Survey. 20 Low coping was defined as scores below the median using an adapted John Henry Active Coping Scale. 21 High perceived stress levels were defined as having a score in the highest tertile for the sample using the Perceived Stress Scale. 22 High stressful life events were defined as scores of Ն150 using the Holmes Rahe Social Readjustment Rating Scale. 23 Low mental and physical health-related quality of life were defined as scores in the lowest tertile of the study sample using the RAND Medical Outcomes Study 36-item tool. 24, 25 
Self-Management Behaviors
Home BP checks and use of lifestyle modifications (weight control, salt reduction, and fruit and vegetable consumption) to lower BP were ascertained by self-report. 26 Assessment of complementary and alternative therapies (including general use, health food and herbal supplements, and relaxation techniques) to help control BP was adapted from a published survey tool. 27, 28 
Blood Pressure
Using standardized forms, trained research staff abstracted seated systolic and diastolic BP measurements from medical charts for clinic visits occurring the year before the baseline and each follow-up interview. BP levels were averaged for visits with Ͼ1 measurement taken. Then, the average BP level for the year before the baseline survey and for each follow-up was calculated. BP data were available for 1845 CoSMO participants.
Medication Adherence
Antihypertensive medication adherence was ascertained using the self-report 8-item Morisky Medication Adherence Scale (MMAS-8). Scores on the MMAS-8 range from 0 to 8. This measure was designed to facilitate the identification of barriers to and behaviors associated with adherence to chronic medications and has been determined to be significantly associated with BP control (PϽ0.05) in cross-sectional studies. 29 Also, it has been shown to be associated with antihypertensive medication pharmacy fill rates. 6, 30 Recently published work established a within-person change in MMAS-8 score of Ն2 points over time to represent a true change in adherence. 31 Thus, decline in adherence was defined as a decrease in MMAS-8 score of Ն2 points in the current study.
Statistical Analyses
Participant baseline characteristics were calculated. Decline in adherence was calculated between the baseline and first follow-up and between the first and second follow-up survey administrations. 31 Pooled logistic regression models were used to compute the adjusted odds ratios (ORs) for an increase in BP associated with a decline in adherence. For individuals with controlled BP at baseline (systolic and diastolic BP Ͻ140/90 mm Hg), the OR for uncontrolled BP (systolic or diastolic BP Ն140 or 90 mm Hg) associated with a decline in adherence was calculated. Because there are no previously validated cut points to define a clinically meaningfully increase in BP, we analyzed 2 different increases in BP, Ͼ0.5 and Ͼ1.0 SDs in systolic and diastolic BPs (1 SD of change in systolic BPϭ12.3 mm Hg; 1 SD of change in diastolic BPϭ6.8 mm Hg). Based on clinical judgment and known confounders, adjustment included age, sex, race, education, marital status, history of diabetes mellitus and cardiovascular disease (myocardial infarction, heart failure, cerebrovascular accident, and peripheral vascular disease), number of medications, number of primary care physician visits, hypertension duration, and reduction of antihypertensive medication because of cost.
Pooled logistic regression models, adjusted for age, sex, race, marital status, education, and comorbidity, were also used to determine associations between risk factors outlined in the previously published conceptual model 11 and described in the Methods section above and a decline in adherence. Then, a multivariable-adjusted pooled logistic regression model, including all of the variables that were significant at the PϽ0.05 level and potential confounders (ie, age, race, education, hypertension duration, and comorbidity), was assembled to identify the factors associated with decline in adherence. Perceived stress was not considered for this final model because it was colinear with both the stressful life events and depressive symptoms scores. All of the analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Results
At the baseline assessment, the mean age was 75.0Ϯ5.6 years, 30.2% were black, 59.0% were women, 56.8% were married, 62.7% had hypertension duration Ն10 years, and 44.3% filled Ն3 classes of antihypertensive medications in the previous year (Table 1) . At baseline, 14.3% of participants had low adherence, whereas 34.0% and 51.7% had medium and high adherence, respectively. Overall, 66.6% had controlled BP.
Over the 2 years of follow-up, 159 participants experienced a decline in antihypertensive medication adherence. The annual rate for a decline in adherence was 4.3%. Of 1229 participants who had controlled BP at baseline, 17.0% had uncontrolled BP at follow-up. After multivariable adjustment, a decline in adherence was associated with an OR for uncontrolled BP of 1.68 (95% CI: 1.01-2.80; Figure) . Increases Ͼ0.5 SD and Ͼ1.0 SD in systolic and diastolic BPs were identified in 12.3% and 4.2% participants, respectively. After multivariable adjustment, decline in adherence was associated with ORs for Ͼ0.5 and Ͼ1.0 SD increases in systolic and diastolic BPs of 1.61 (95% CI: 1.00 -2.57) and 2.55 (95% CI: 1.36 -4.77), respectively.
The annual rate of decline in antihypertensive medication adherence is reported by participant characteristics in Table  S1 (please see the online Data Supplement at http://hyper. ahajournals.org). Being female, married, and taking calcium channel blockers were associated with a lower adjusted OR for a decline in adherence (Table 2) . Depressive symptoms; low health-related quality of life (physical); high perceived stress; and having a high stressful life event score were associated with an increased adjusted OR for a decline in adherence. In the final multivariable-adjusted model, depressive symptoms and a high stressful life events score were associated with a decline in adherence, whereas female sex, being married, and taking calcium channel blockers remained protective of a decline in adherence (Table 3) .
Discussion
In this large cohort of patients with hypertension, only 51.7% had high adherence, and 66.6% had controlled BP at baseline. The annual rate of decline in adherence was 4.3%, and a decline in adherence was associated with a 1.68-fold increase in uncontrolled BP at follow-up. Two modifiable factors (depressive symptoms and use of specific antihypertensive medication classes) associated with decline in adherence were identified. Other nonmodifiable factors (eg, sex and marital status), which may still be helpful in identifying patients at risk for decline in antihypertensive medication adherence and worsening BP, were also identified. Despite the growing interest in patient adherence to antihypertensive medications, few data are available on changes in adherence over time. The current study extends previous work by providing new data on decline in self-reported antihypertensive medication adherence, BP control, and risk factors for decline. Previous studies using pharmacy data have revealed that persistence to pharmacological antihypertensive therapy declines over time. In one study, 3% of patients with established hypertension became nonpersistent (determined using prescription data) to their antihypertensive medication regimen at 1.0 year and 18% at 4.5 years. 10 In our analysis of adults with established hypertension, a 4.3% annual rate of decline in self-reported antihypertensive medication was present. The current study goes beyond previous research using prescription data and identified an association of decline in selfreported adherence with uncontrolled BP obtained from routine outpatient visit data. This finding may increase confidence that assessment of changes in antihypertensive medication adherence may be useful in managing patients in real world clinical practice.
The current longitudinal analysis is consistent with crosssectional studies reporting that being female and married are associated with better adherence rates. 10, 32 Our results extend previous cross-sectional data by revealing a significant protective effect of being female and married on decline in adherence.
Depression is common in patients with hypertension. Depressive symptoms are associated with poor BP control, complications of hypertension, 33 and low antihypertensive medication adherence. 34 -36 Less is known about the relationship between depressive symptoms and changes in antihypertensive medication adherence over time. In our study, the presence of depressive symptoms was the strongest risk factor for a decline in antihypertensive medication adherence over 2 years of follow-up. Comanagement of hypertension and depression has been suggested to improve adherence rates and healthcare outcomes for both conditions. 37, 38 In the current analyses, more stressful life events were associated with a decline in adherence. Previous research suggests that patients experiencing stressful life events may have reduced motivation or ability to continue psychiatric medications. 39 Increased stressful life events have also been associated with the onset or exacerbation of chronic disease. 40 -42 Although the stress from major life changes could result in exacerbation of disease directly, the disruption of medication-taking routines associated with major life events could mediate this relationship.
Although other studies have shown class-specific benefits on medication-taking behavior for drugs with once daily dosing and favorable tolerability, [43] [44] [45] [46] [47] [48] the protective effect of calcium channel blockers on decline in adherence observed in the present study can only be speculated. First, calcium channel blockers are recommended for patients with a compelling indication (ie, high coronary disease risk or diabetes mellitus) or higher levels of BP. 49 Thus, patients taking these Figure. Decline in medication adherence associated with increased blood pressure at follow-up. *Uncontrolled blood pressure was defined as Ն140/90 mm Hg at follow-up among those with controlled BP at baseline. Odds ratios were adjusted for age, sex, race, education, marital status, history of diabetes mellitus or cardiovascular disease (myocardial infarction, heart failure, cerebrovascular accident, and peripheral vascular disease), number of medications, number of primary care physician visits, hypertension duration, and reduction of antihypertensive medication because of cost. SBP indicates systolic blood pressure; DBP, diastolic blood pressure. Note: 1 SD of change in systolic blood pressureϭ12.3 mm Hg; 1 SD of change in diastolic blood pressureϭ6.8 mm Hg.
drugs may have more severe disease reinforcing the importance of medication adherence. Furthermore, significant improvements in depressive symptoms in patients randomized to verapamil versus atenolol suggest positive mood-related effects of this calcium channel blocker, 50 which may impact adherence. Lastly, the reduced intraindividual variation in systolic BP observed in patients taking calcium channel MMAS-8 decline indicates Morisky Medication Adherence Scale-8 item score decline of Ն2 points. Reference groups were as follows: age Ͻ75 y, male, nonblack race, unmarried, less than high school education, medium or high hypertension knowledge, hypertension duration Ͻ10 y, Charlson comorbidity score Ͻ2, body mass index Ͻ30, Ͻ3 classes of antihypertensive medication, no calcium channel blocker use, no ␤-blocker use, no angiotensin receptor blocker use, no diuretic use, no angiotensin-converting enzyme inhibitor use, satisfied with overall health care, satisfied with communication, satisfied with access to health care, no reduction of medications because of cost, Ͻ6 visits to the primary care physician, did not fill antihypertensive medication in tier 3, current or former smoker, Ն2 alcoholic beverages per week, normal sexual functioning, no depressive symptoms, medium or high health-related quality of life (mental), medium or high health-related quality of life (physical), medium or high social support, medium or high coping, medium or low stress, stressful life events score Ͻ150, no complementary and alternative medicine use, no report of each lifestyle modification (ie, blood pressure checks at home, trying to control or lose weight, cutting down on sodium intake, or increasing No. of fruits and vegetables). *Data were adjusted for age, sex, race, marital status, education, and comorbidity.
†PϽ0.05. ‡PϽ0.01. §Data were in the previous year. blockers 51 may result in more balanced BP levels over time, patients feeling better, and higher adherence. The current study findings support consideration of medication class effects on medication-taking behavior when treating older patients with established hypertension.
Limitations and Strengths
The medication adherence measure was based on self-report, which may have led to overestimation of adherence because of social desirability and recall biases. However, previous work found no association between the MMAS-8 and social desirability. 29 Of note, there is no gold standard for measuring medication adherence, and each method has limitations. 32, 52 Although pharmacy fill has been widely reported from managed care organizations, Ͻ30% of US adults receive care in settings where pharmacy fill data are readily available. 53 BP was abstracted from medical charts and not measured using a study protocol. The current study was limited to English-speaking adults Ն65 years of age with health insurance in one region of the United States. However, almost all US citizens Ն65 years of age have health insurance and pharmacy benefits through Medicare. 2, 54 Despite these limitations, the inclusion of a large sample of diverse community-dwelling older adults, longitudinal design, broad data collection, availability of administrative data, and high follow-up capture rate are strengths of this study. The restriction of our sample to older adults in a managed care setting minimizes the confounding effects of health insurance, access to medical care, and employment status in older adults.
Perspectives
Low adherence to medications is a growing concern because of increasing evidence that it is common and associated with adverse outcomes and higher healthcare costs. 55 Furthermore, the use of performance measures that reward quality based on the attainment of BP control reinforces the importance of continuous medication adherence 56 and prevention of decline in adherence. Nevertheless, routine assessment of medication adherence is not done. 57 Providers may not think of a decline in adherence as the reason for uncontrolled BP, are uncertain about quantifying adherence, 30, 58 or are unaware of modifiable factors associated with decline in adherence. Our study provides information about decline in self-reported adherence in older adults, which may be used to identify patients at risk for worsening adherence and BP control in clinical practice. Further research is warranted to determine whether interventions to overcome barriers to adherence can prevent the decline in adherence over time.
